Physician profile
Rohit Gupta
NPI 1538302492
$2,600.20
in general payments reported to CMS, 2019-2025
22 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.53 · 2020: $77.34 · 2021: $592 · 2022: $680 · 2023: $519 · 2024: $383 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $682.50 | 2021-2022 | |
| Pfizer INC. | $421.85 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $355.63 | 2019-2025 | Jynarque |
| Kestra Medical Technology Services, INC. | $164.23 | 2023-2024 | Assure Wcd |
| Edwards Lifesciences Corporation | $158.52 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $126.80 | 2023-2025 | |
| Biogen, INC. | $124.85 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $89.38 | 2021-2025 | Camzyos, Eliquis |
| Astellas Pharma US INC | $87.99 | 2021 | |
| Amgen INC. | $70.02 | 2022-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.23 | 2022-2024 | Jardiance |
| Amarin Pharma, INC. | $41.16 | 2021 | |
| Sanofi-Aventis U.S. LLC | $36.86 | 2022-2023 | |
| Inspire Medical Systems, INC. | $35.14 | 2024-2025 | Inspire |
| Cvrx, INC. | $33.74 | 2023 | Barostim Neo System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.80 | 2022-2023 | Verquvo |
| Lantheus Medical Imaging, INC. | $20.57 | 2022 | |
| Novo Nordisk INC | $17.43 | 2024 | Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $15.85 | 2025 | Amvuttra |
| Kiniksa Pharmaceuticals, LTD. | $15.01 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.88 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.